Alexander Belcredi MBA

Alexander Belcredi has been working in the pharmaceutical space for over a decade. He spent nine years at BCG where he was part of the global health care team, focusing on Pharma and Medtech. While at BCG, Belcredi became acutely aware of the urgent need to develop alternatives to antibiotics and was fascinated by the role that phage therapy can play. In 2017, he co-founded PhagoMed Biopharma GmbH, a biotech company developing phage-based pharmaceuticals to treat bacterial infections, where he now serves as CEO. Belcredi holds an MA in Modern History and Economics from the University of St. Andrews as well as an MBA from INSEAD.